
Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510



LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Pag

2. AddressCheck if diffferent than previously report 2550 M Street, NW	
Washington, DC 20037	
3. Principal Place of Business (if different from line 2) City: State/Zip (or Country)	
4. Contact Name Telephone E-mail (optional) James B. Christian 202-457-6484	5. Senate ID # 30906-5471
7. Client NameSelf Jerome Stevens Pharmaceuticals	6. House ID # 31917442
TYPE OF REPORT 8. Year 2001 Midyear (January 1-Ju	ne 30) X OR Year End (July 1-December 31)
	-
9. Check if this filing amends a previously filed version of	this report
10. Check if this is a Termination Report ⇒ Termination	n Date 11. No Lobbying Activity
INCOME OR EXPENSES - Complete Either I	ine 12 OR Line 13
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this period were:
Less than \$10,000 _X_	Less than \$10,000 _
\$10,000 or more \Rightharpoonup \frac{1}{\text{Income (nearest \$20,000)}}	\$10,000 or more \$ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by anyother entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indice expense accounting method. See instructions for design of options.
	_Method A. Reporting amounts using LDA defini _Method B. Reporting amounts under section 603 the Internal Revenue Code _Method C. Reporting amounts under section 162 Internal Revenue Code
Signature	

Registrant Name Patton Boggs LLP

Client Name Jerome Stevens Pharmaceuticals

LOBBYING ACTIVITY. Select as many as necessary to reflect the general issue areas in which the registrant eng lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide informa requested. Attach additional page(s) as needed.

- 15. General issue area code HCR (one per page)
- 16. Specific lobbying issues

Regulatory status of levothyroxine sodium products

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives Senate

Form LD-2 (Rev 06/98)

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	N
Stuart Pape	None	
Paul Rubin	None	
Daniel Kracov	None	

19. Interest of each foreign entity in the specific issues listed on line 16 above X_ Check if None

Signature	Date	
Printed Name and Title James B. Christian, Partner		

Filing #a732377e-bd5c-4848-9c73-f0ef446d1409 - Page 3 of 8

Registrant Name Patton Boggs LLP

Client Name Jerome Stevens Pharmaceuticals

LOBBYING ACTIVITY. Select as many as necessary to reflect the general issue areas in which the registrant eng lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide informa requested. Attach additional page(s) as needed.

- 15. General issue area code MED (one per page)
- 16. Specific lobbying issues

Regulatory status of levothyroxine sodium products

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)		
Stuart Pape	None		
Paul Rubin	None		
Daniel Kracov	None		

19,	Interest of	of each	foreign	entity in	the s	pecific issu	ues listed	on line	16 above	X	Check if None

Signature	Date
Printed Name and Title James B. Christian, Partner	

Form LD-2 (Rev 06/98)

LOBBYING ACTIVITY. Select as many as necessary to reflect the general issue areas in which the registrant englobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide informa requested. Attach additional page(s) as needed.

- 15. General issue area code PHA (one per page)
- 16. Specific lobbying issues

Regulatory status of levothyroxine sodium products

17. House(s) of Congress and Federal agencies contacted __ Check if None

House of Representatives Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)			
Stuart Pape	None			
Paul Rubin	None			
Daniel Kracov	None			

19. Interest of each foreign entity in the specific issues listed on line 16 above X_ Check if None

Date 8/9/01

Printed Name and Title James B. Christian, Partner

Form LD-2 (Rev 06/98)